Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis.

Authors: Graf, T; Thiele, T; Klingebiel, R; Greinacher, A; Schabitz, W-R; Greeve, I.

Affiliations: Department of Neurology, Evangelisches Klinikum Bethel, OWL University Hospital, Bielefeld University, Bielefeld‑Bethel Campus, Bielefeld, Germany; Department of Transfusion Medicine, Institute for Immunology and Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany; Department of Neuroradiology, Evangelisches Klinikum Bethel, OWL University Hospital, Bielefeld University, Bielefeld‑Bethel Campus, Bielefeld, Germany.

Publication: Journal of neurology; June 2021

Abstract: Here, we report a case of a 29-year-old male public healthcare professional, vaccinated with the recombinant adenoviral vector encoding the spike protein antigen of SARSCoV-2 (ChAdOx1 nCov-19, AstraZeneca) on the 29th of March (day 1). Nine days later, he developed headache and abdominal pain, on day 12 emesis and abdominal cramps. On day 14, he was urgently admitted to a hospital due to severe headache and hematemesis. Upon admission thrombocytopenia of 32/nL was detected. (…)